Physicians' Academy for Cardiovascular Education

LDL-c & PCSK9i in Clinical Cardiology

European experts discuss the importance of targeting LDL-c in patients at increased CV risk and the potential role of PCSK9 inhibition - More videos to be added

Progressive CAD despite low LDL-C, an elusive disease?

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot

Cholesterol guidelines in need of major changes?

5' education - Jan. 25, 2019 - Kausik Ray, François Mach

What is the science and outcome supporting lower LDL-c targets?

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana

LDL-c as target in cardiology: The road towards lower targets

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands

Guidelines and the role of non-statin therapies for high risk ASCVD patients

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Landmark trials with PCSK9 inhibitors

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK

PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)

3' education - June 29, 2018 - John Chapman - Paris, France

Learn more about the mission of PACE-CME

3' education - Aug. 31, 2018

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

Early intervention for lifetime CV risk reduction

10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK

Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL. USA - Prof. Wouter Jukema - LUMC, The Netherlands

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France

Diabetic dyslipidemia and residual risk in the era of LDL control

10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA

Sustained LDL-c reduction upon dose adjustment of PCSK9 inhibitor

Literature - Feb. 20, 2019 - Dufour R et al., - J Clin Lipidol. 2019

In an open-label extension study, consistent and sustained LDL-c reduction was seen upon changing the dose of alirocumab based on LDL-c level, allowing for an individualized approach.

Progressive CAD despite low LDL-C, an elusive disease?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema
In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.

Large reduction of major vascular events with statins in older individuals

Literature - Feb. 11, 2019 - Cholesterol Treatment Trialists’ Collaboration - The Lancet 2019

A meta-analysis of 28 large RCTs including more than 14.000 individuals aged >75 years showed that the use of statins resulted in significant reductions of major vascular events regardless of age.

PCSK9 inhibitor reduces first and subsequent nonfatal CV events and death after ACS

Literature - Feb. 11, 2019 - Szarek M et al., - J Am Coll Cardiol. 2019

In a total events analysis of ODYSSEY OUTCOMES, treatment with alirocumab reduced the total burden of fatal and nonfatal CV events in a post-ACS population, as compared with placebo.

What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot
Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.

Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.

Clinical benefit of lowering TG and LDL-c proportional to absolute change in ApoB

Literature - Feb. 5, 2019 - Ference BA et al., - JAMA. 2019

Mendelian randomization study suggests that CHD risk reduction of TG-lowering LPL variants and LDL-c lowering LDLR variants are similar per unit difference in ApoB-level.

No interindividual variation in robust LDL-c reduction with PCSK9 inhibition in CVD

Literature - Jan. 29, 2019 - Qamar A et al. - JAMA Cardiology 2018

Reduction of LDL-c levels was highly consistent with evolocumab therapy among CVD patients as demonstrated by a subanalysis of the FOURIER trial.

Cholesterol guidelines in need of major changes?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 25, 2019 - Kausik Ray, François Mach
New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.

New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.

Magnitude of the association of ideal CV health with lower diabetes risk varies by glycemic status

Literature - Jan. 24, 2019 - joseph JJ et al. - Diabetologia 2019

High number of ideal CV health metrics is associated with low incidence of diabetes in subjects with normal fasting glucose, but not in those with impaired fasting glucose.

What is the science and outcome supporting lower LDL-c targets?

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana
Prof. Masana explains whether achieving very low LDL-c levels with current treatments is safe and might cause any biological problems.

Prof. Masana explains whether achieving very low LDL-c levels with current treatments is safe and might cause any biological problems.

LDL-c as target in cardiology: The road towards lower targets

Expert Meeting on LDL-c & PCSK9 inhibition in high CV risk patients

5' education - Jan. 22, 2019 - John Kastelein, Chris Packard
Prof. Kastelein discusses the biology of LDL with prof. Packard and which strategies are available for LDL-c lowering in CVD prevention in high-risk patients.

Prof. Kastelein discusses the biology of LDL with prof. Packard and which strategies are available for LDL-c lowering in CVD prevention in high-risk patients.

Treatment effect of PCSK9-inhibitor on major coronary events by baseline Lp(a) level in ASCVD

Literature - Jan. 21, 2019 - O’Donoghue ML et al. - Circulation 2018

In a subanalysis of the FOURIER trial, treatment with evolocumab in patients with higher baseline Lp(a) resulted in non-significant greater percent reduction and greater absolute reduction of coronary events, compared to those with low baseline Lp(a).

LDL-c & PCSK9i in Clinical Cardiology
LDL-c & PCSK9i in Clinical Cardiology
LDL-c & PCSK9i in Clinical Cardiology
LDL-c & PCSK9i in Clinical Cardiology
LDL-c & PCSK9i in Clinical Cardiology